Local management of unresectable lung atypical carcinoid tumor: a case report and review of literature

Authors

  • Joana Martins Pisco Department of Radiation Oncology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
  • Pedro Miguel Silva Department of Radiation Oncology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
  • André Pinheiro Figueiredo Department of Radiation Oncology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
  • Manuel Carmo Silva Department of Radiation Oncology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal
  • Maria Filomena Pina Department of Radiation Oncology, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal

DOI:

https://doi.org/10.18203/2349-3933.ijam20234162

Keywords:

Neuroendocrine tumors,, Radiotherapy, Local control, Unresectable

Abstract

Neuroendocrine tumors comprise a rare but increasing heterogeneous group of malignancies arising from neuroendocrine cells, most commonly from the lung and gastrointestinal tract. Due to the vast histopathological differentiation of each subtype and the scarce clinical data published, choosing the most effective therapy can be challenging. Radiotherapy can play a significant role in the treatment of locally advanced metastatic tumors, however there is a lack of randomized clinical trials in this setting. This article reviews the current knowledge on the classification and treatment of unresectable lung atypical carcinoids. We present a clinical case of a ULAC treated with systemic therapy and RT in different settings of the disease. The subject is a 48 years old male, diagnosed with a well differentiated pulmonary NET, classified as cT4N3M1b (supraclavicular and mediastinal adenopathies and an adrenal metastatic lesion) with disease progression after systemic treatment, and with superior vena cava compression. The primary tumor and involved nodal areas were treated to 54Gy/30 fractions using VMAT. SBRT was given to the metastatic left adrenal gland. Five months after RT, CT showed a volumetric reduction of <25% of the thoracic disease and adrenal gland’s lesion stability. The disease remained stable for the next year and a half, when local and distant progression occurred, starting systemic treatment. A year and a half later, the patient presented with brain metastasis and underwent radiosurgery. At last follow-up, 5 years after diagnosis, the patient maintains treatment with capecitabine and temozolomide and is clinically stable. Definitive RT should be considered in the management of ULAC to improve local control.

References

Hendifar AE, Marchevsky AM, Tuli R. Neuroendocrine Tumors of the Lung: Current Challenges and Advances in the Diagnosis and Management of Well-Differentiated Disease. J Thorac Oncol. 2017;12(3):425-36.

Gheorghișan-Gălățeanu AA, Ilieșiu A, Lambrescu IM, Țăpoi DA. The Complex Histopathological and Immunohistochemical Spectrum of Neuroendocrine Tumors-An Overview of the Latest Classifications. Int J Mol Sci. 2023;24(2):1418.

Neuroendocrine and adrenal tumors. Available at: https://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf. Accessed on 14 July 2023.

European Neuroendocrine Tumor Society. Available at: https://www.enets.org/standardised-reports.html. Accessed on 14 July 2023.

Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387(10022):968-77.

Chen KS, Lawhn-Heath C, Behr S, Juarez R, Whitman J, Paciorek A, Nakakura EK, Fidelman N, Feng MU, Bergsland EK, Anwar M. Outcomes after high-dose radiation in the management of neuroendocrine neoplasms. PLoS One. 2021;16(6):e252574.

Chen WC, Baal JD, Baal U, Pai J, Gottschalk A, Boreta L, et al. Stereotactic Body Radiation Therapy of Adrenal Metastases: A Pooled Meta-Analysis and Systematic Review of 39 Studies with 1006 Patients. Int J Radiat Oncol Biol Phys. 2020;107(1):48-61.

König L, Häfner MF, Katayama S, Koerber SA, Tonndorf-Martini E, Bernhardt D, et al. Stereotactic body radiotherapy (SBRT) for adrenal metastases of oligometastatic or oligoprogressive tumor patients. Radiat Oncol. 2020;15(1):30.

Scouarnec C, Pasquier D, Luu J, le Tinier F, Lebellec L, Rault E, et al. Usefulness of Stereotactic Body Radiation Therapy for Treatment of Adrenal Gland Metastases. Front Oncol. 2019;9:732.

Toesca DAS, Koong AJ, von Eyben R, Koong AC, Chang DT. Stereotactic body radiation therapy for adrenal gland metastases: Outcomes and toxicity. Adv Radiat Oncol. 2018;3(4):621-9.

Conibear J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, et al. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open. 2018;8(4):e020690.

Maiuri F, Cappabianca P, Del Basso De Caro M, Esposito F. Single brain metastases of carcinoid tumors. J Neurooncol. 2004;66(3):327-32.

Cao F, Sada DM, Lai S, Sada YH. Stereotactic Radiosurgery for Carcinoid Brain Metastasis: A Case Report. Cureus. 2019;11(8):e5509.

Truong MT, St Clair EG, Donahue BR, Rush SC, Miller DC, Formenti SC, et al. Results of surgical resection for progression of brain metastases previously treated by gamma knife radiosurgery. Neurosurgery. 2006;59:86-97.

Telera S, Fabi A, Pace A, Vidiri A, Anelli V, Carapella CM, et al. Radionecrosis induced by stereotactic radiosurgery of brain metastases: results of surgery and outcome of disease. J Neurooncol. 2013;113(2):313-25.

Kuwahara Y, Tomita K, Urushihara Y, Sato T, Kurimasa A, Fukumoto M. Association between radiation- induced cell death and clinically relevant radioresistance. Histochem Cell Biol. 2018; 150(6):649-59.

Sneed PK, Mendez J, Vemer-van den Hoek JG, Seymour ZA, Ma L, Molinaro AM, Fogh SE, Nakamura JL, McDermott MW. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors. J Neurosurg. 2015;123:373-86.

Loi M, Caini S, Scoccianti S, Bonomo P, De Vries K, Francolini G, et al. Stereotactic reirradiation for local failure of brain metastases following previous radiosurgery: systematic review and meta-analysis. Crit Rev Oncol Hematol. 2020.

Kano H, Kondziolka D, Zorro O, Lobato-Polo J, Flickinger JC, Lunsford LD. The results of resection after stereotactic radiosurgery for brain metastases. J Neurosurg. 2009;111:825-31.

Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295:2483-91.

Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. Int J Radiat Oncol Biol Phys. 2000;47:291-8.

Rades D, Pluemer A, Veninga T, Hanssens P, Dunst J, Schild SE. Whole-brain radiotherapy versus stereotactic radiosurgery for patients in recursive partitioning analysis classes 1 and 2 with 1 to 3 brain metastases. Cancer. 2007;110:2285-92.

Downloads

Published

2023-12-30

Issue

Section

Case Reports